MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations

Por Kerstjens, Mark, Driessen, Emma M.C., Willekes, Merel, Pinhanços, Sandra S., Schneider, Pauline, Pieters, Rob, Stam, Ronald W.
Publicado no Oncotarget (2016)

Frequencies and prognostic impact of RAS mutations in MLL-rearranged acute lymphoblastic leukemia in infants

Por Driessen, Emma M.C., van Roon, Eddy H.J., Spijkers-Hagelstein, Jill A.P., Schneider, Pauline, de Lorenzo, Paola, Valsecchi, Maria Grazia, Pieters, Rob, Stam, Ronald W.
Publicado em 2013

Identification of Genes Transcriptionally Responsive to the Loss of MLL Fusions in MLL-Rearranged Acute Lymphoblastic Leukemia

Por van der Linden, Marieke H., Seslija, Lidija, Schneider, Pauline, Driessen, Emma M. C., Castro, Patricia Garrido, Stumpel, Dominique J. P. M., van Roon, Eddy, de Boer, Jasper, Williams, Owen, Pieters, Rob, Stam, Ronald W.
Publicado no PLoS One (2015)